249 related articles for article (PubMed ID: 3522444)
1. Treatment of post-menopausal osteoporosis with phosphate and intermittent calcitonin.
Kuntz D; Marie P; Berhel M; Caulin F
Int J Clin Pharmacol Res; 1986; 6(2):157-62. PubMed ID: 3522444
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
Hodsman AB; Fraher LJ; Ostbye T; Adachi JD; Steer BM
J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
[TBL] [Abstract][Full Text] [Related]
3. Clinical, biochemical and histological results of a double-blind trial with 1,25-dihydroxyvitamin D3, estradiol and placebo in post-menopausal osteoporosis.
Caniggia A; Delling G; Nuti R; Lorè F; Vattimo A
Acta Vitaminol Enzymol; 1984; 6(2):117-28. PubMed ID: 6388277
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms underlying the effects of phosphate and calcitonin on bone histology in postmenopausal osteoporosis.
Marie PJ; Caulin F
Bone; 1986; 7(1):17-22. PubMed ID: 3964494
[TBL] [Abstract][Full Text] [Related]
5. [Effect of low calcitonin doses on bone remodeling in postmenopausal women with high bone turnover rate].
Campusano C; López JM; Campino C; Cárdenas I; Rojas A
Rev Med Chil; 2000 Apr; 128(4):387-91. PubMed ID: 10962855
[TBL] [Abstract][Full Text] [Related]
6. Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis.
Agnusdei D; Zacchei F; Bigazzi S; Cepollaro C; Nardi P; Montagnani M; Gennari C
Drugs Exp Clin Res; 1989; 15(2):97-104. PubMed ID: 2661184
[TBL] [Abstract][Full Text] [Related]
7. Prevention of bone mineral loss in postmenopausal women by norethisterone.
Abdalla HI; Hart DM; Lindsay R; Leggate I; Hooke A
Obstet Gynecol; 1985 Dec; 66(6):789-92. PubMed ID: 4069480
[TBL] [Abstract][Full Text] [Related]
8. [Calcitonin, calcium lactate-gluconate + potassium phosphate, calcium phosphate: changes induced in the biology of the patient with multiple fractures].
de Bastiani G; Nogarin L; Perusi M
Clin Ortop; 1974; 25(4):199-204. PubMed ID: 4471239
[TBL] [Abstract][Full Text] [Related]
9. Effects of prolonged administration of porcine calcitonin in postmenopausal osteoporosis.
Jowsey J; Riggs BL; Goldsmith RS; Kelly PJ; Arnaud CD
J Clin Endocrinol Metab; 1971 Nov; 33(5):752-8. PubMed ID: 4942159
[No Abstract] [Full Text] [Related]
10. Calcitonin treatment of post-menopausal osteoporosis. Evaluation of efficacy by principal components analysis.
Milhaud G; Talbot JN; Coutris G
Biomedicine; 1975 May; 22(3):223-32. PubMed ID: 809068
[TBL] [Abstract][Full Text] [Related]
11. Bone histomorphometry in the pathophysiological evaluation of primary and secondary osteoporosis and various treatment modalities.
Steiniche T
APMIS Suppl; 1995; 51():1-44. PubMed ID: 7669370
[TBL] [Abstract][Full Text] [Related]
12. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
[TBL] [Abstract][Full Text] [Related]
13. [Histomorphometric and biological data on osteoporosis due to immobilization].
Minaire P; Meunier P; Edouard C; Bernard J; Courpron P
Rev Rhum Mal Osteoartic; 1975; 42(7-9):479-88. PubMed ID: 1179130
[TBL] [Abstract][Full Text] [Related]
14. [Effect of elcatonin on experimental osteoporosis induced by ovariectomy and low calcium diet in beagles].
Hori M; Takahashi H; Konno T; Inoue J; Haba T; Sakurada T; Noda T; Fujimoto K
Nihon Yakurigaku Zasshi; 1984 Jul; 84(1):91-8. PubMed ID: 6489866
[TBL] [Abstract][Full Text] [Related]
15. Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment.
Miki T; Nakatsuka K; Naka H; Masaki H; Imanishi Y; Ito M; Inaba M; Morii H; Nishizawa Y
J Bone Miner Metab; 2004; 22(6):569-76. PubMed ID: 15490267
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of the effectiveness of 17-beta-estradiol and calcitonin in women with postmenopausal bone loss].
Stĕpán J; Formánková J; Masatová A; Michalský M; Rosenová Z
Cas Lek Cesk; 1997 Apr; 136(8):242-8. PubMed ID: 9264868
[TBL] [Abstract][Full Text] [Related]
17. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography.
Borah B; Dufresne TE; Chmielewski PA; Johnson TD; Chines A; Manhart MD
Bone; 2004 Apr; 34(4):736-46. PubMed ID: 15050906
[TBL] [Abstract][Full Text] [Related]
18. Effects of a one-year administration of phosphate and intermittent calcitonin on bone-forming and bone-resorbing cells in involutional osteoporosis: a histomorphometric study.
Alexandre C; Chappard D; Caulin F; Bertrand A; Palle S; Riffat G
Calcif Tissue Int; 1988 Jun; 42(6):345-50. PubMed ID: 3135102
[TBL] [Abstract][Full Text] [Related]
19. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study.
Mazzuoli GF; Passeri M; Gennari C; Minisola S; Antonelli R; Valtorta C; Palummeri E; Cervellin GF; Gonnelli S; Francini G
Calcif Tissue Int; 1986 Jan; 38(1):3-8. PubMed ID: 3079649
[TBL] [Abstract][Full Text] [Related]
20. [Recent acquisitions in therapy of osteoporosis of various etiologies with calcitonin].
Vigo PL; Di Ciano L; Girardello R; Reschini E; Polli E
Recenti Prog Med; 1977 Jun; 62(6):649-70. PubMed ID: 578332
[No Abstract] [Full Text] [Related]
[Next] [New Search]
